Abiopharma

🔍 FROST PHILLIP MD ET AL (Director)

Company: Cocrystal Pharma, Inc. (COCP)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Acquired 24,615 shares of Stock Options (Right to Buy) at $1.1 per share (Derivative)
  Date: 2026-01-09 | Code: A | Expires: 2036-01-09 | equity_swap_involved: 0 | shares_owned_after: 24,615.00 | transaction_form_type: 4 | Footnotes: F1, F1

Footnotes:

• F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.
• REMARKS: This Form 4 does not include any of the securities owned directly by OPKO Health, Inc., a company of which Dr. Frost is the Chairman of the Board and Chief Executive Officer, concerning the securities of which Dr. Frost does not hold voting and investment control. Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.